All articles tagged with #kyverna therapeutics
Kyverna Therapeutics saw its shares surge over 50% on its first day as a public biotech company after pricing at $22 and raising $319 million, following five years of development and private fundraising. CEO Peter Maag outlined plans for cell therapy in immune diseases, emphasizing the company's long journey and the support of its "Kyverna village."
California biotech Kyverna Therapeutics has raised $319 million in its Nasdaq debut, pricing its shares at $22 apiece and valuing the company at about $898 million. The successful IPO reflects investor enthusiasm for the company's work in bringing CAR-T cell therapies into the autoimmune world, beyond their initial focus on blood cancer, as it exceeded its original fundraising target of $182 million and increased its price range to $20 to $21 before final pricing.